Experienced Biotech Business Development and Investment Banker Enhances
EntreMed's Senior Management Team
ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the appointment of Mr. Thomas H. Bliss, Jr. as Senior Vice President, Corporate and Business Development. Mr. Bliss has been elected an executive officer by EntreMed's Board of Directors and will report to the Company's President and Chief Executive Officer, Mr. James S. Burns.
Most recently the Executive Director, Licensing at Amgen, Mr. Bliss brings nearly 20 years biotechnology business development and healthcare investment banking experience to EntreMed. In his most recent role at Amgen, Mr. Bliss was responsible for international licensing, licensing operations oversight and the coordination and communication of Amgen's China/India Research Activities Initiative. Previous to that, Mr. Bliss was responsible for directing all Amgen acquisition activity, including the acquisition of Abgenix. Prior to joining Amgen in 2004, Mr. Bliss served as Vice President, BioPharmaceuticals Business Development at Baxter BioScience, where he directed all licensing and acquisition activities.
Mr. Bliss' career in life science business development began in 1994
with Johnson & Johnson where he provided analytical support for all
franchises and participated in the creation of billion dollar
cardiovascular access and orthopedic businesses. The first
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved